Mu-selective, but not non-selective, opioid receptor antagonism reduces L-DOPA induced dyskinesia in the MPTP macaque model of Parkinson's disease

被引：0
|
作者：
Fox, S. H.
Koprich, J. B.
Johnston, T. H.
Goodman, A.
Le Bourdonnec, B.
Dolle, R. E.
DeHaven, R. N.
DeHaven, D. L.
Little, P. J.
Brotchie, J. M.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S412 / S412
页数：1
相关论文
共 50 条
  • [21] TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease
    Ikeda, Ken
    Yoshikawa, Satoru
    Kurokawa, Takahiro
    Yuzawa, Natsumi
    Nakao, Kaoru
    Mochizuki, Hidenori
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 620 (1-3) : 42 - 48
  • [22] Possible role for chlorpheniramine in the treatment of l-DOPA induced dyskinesia in Parkinson’s disease
    Petros N. Karamanakos
    Periklis Pappas
    Marios Marselos
    Pharmacy World & Science, 2008, 30 : 1 - 2
  • [23] Initiation of entacapone with L-DOPA further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease
    Jenner, P
    Al-Barghouthy, G
    Smith, L
    Kuoppamaki, M
    Jackson, M
    Rose, S
    Olanow, W
    NEUROLOGY, 2002, 58 (07) : A374 - A375
  • [24] Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease
    Karamanakos, Petros N.
    Pappas, Periklis
    Marselos, Marios
    PHARMACY WORLD & SCIENCE, 2008, 30 (01): : 1 - 2
  • [25] Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications
    Hauser, R. A.
    Gertner, J. M.
    Okamoto, M.
    Reed, R. F.
    Sage, J. I.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S118 - S118
  • [26] Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats
    Izurieta-Sánchez, P
    Sarre, S
    Ebinger, G
    Michotte, Y
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (01) : 33 - 42
  • [27] The cannabinoid receptor antagonist SR141716A reduces L-dopa-induced dyskinesia in the MPTP-treated primate model of Parkinson's disease.
    Hill, M
    Fox, S
    Henry, B
    Peggs, D
    Crossman, AR
    Brotchie, JM
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 324 - 324
  • [28] Receptor Heteromers in Parkinson's Disease and L-DOPA-Induced Dyskinesia
    Fiorentini, Chiara
    Savoia, Paola
    Savoldi, Daria
    Missale, Cristina
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (08) : 1101 - 1113
  • [29] The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of parkinson's disease
    Henry, B
    Fox, SH
    Peggs, D
    Crossman, AR
    Brotchie, JM
    MOVEMENT DISORDERS, 1999, 14 (05) : 744 - 753
  • [30] The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia
    Gutierrez-Valdez, Ana L.
    Garcia-Ruiz, Ricardo
    Anaya-Martinez, Veronica
    Torres-Esquivel, Carmen
    Espinosa-Villanueva, Jesus
    Reynoso-Erazo, Leonardo
    Tron-Alvarez, Rocio
    Aley-Medina, Patricia
    Sanchez-Betancourt, Javier
    Montiel-Flores, Enrique
    Avila-Costa, Maria R.
    BEHAVIOURAL PHARMACOLOGY, 2013, 24 (08): : 640 - 652
12345